Literature DB >> 20126607

Side Effects of alpha-Blocker Use: Retrograde Ejaculation.

Steven A Kaplan1.   

Abstract

There are currently 5 alpha-blockers that are approved by the US Food and Drug Administration to treat lower urinary tract symptoms (LUTS). The American Urological Association guidelines committee believes that all alpha-blockers are equally effective. However, alpha-blockers differ in their likelihood of causing abnormal ejaculation. This article discusses the effects on ejaculatory function, and specifically retrograde ejaculation, of the currently available alpha-blockers being used to treat men with LUTS due to benign prostatic hyperplasia.

Entities:  

Keywords:  Benign prostatic hyperplasia; Lower urinary tract symptoms; Retrograde ejaculation; α-Blockade

Year:  2009        PMID： 20126607      PMCID： PMC2812888     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  17 in total

1.  Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.

Authors:  Kazuki Kawabe; Masaki Yoshida; Yukio Homma
Journal:  BJU Int       Date:  2006-08-31       Impact factor: 5.588

2.  Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia.

Authors:  Satoshi Tatemichi; Yoshitaka Tomiyama; Itaru Maruyama; Shinya Kobayashi; Kumi Kobayashi; Ayaka Maezawa; Mamoru Kobayashi; Yoshinobu Yamazaki; Nobuo Shibata
Journal:  Neurourol Urodyn       Date:  2006       Impact factor: 2.696

3.  [Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213)].

Authors:  Satoshi Tatemichi; Kumi Kobayashi; Ayaka Maezawa; Mamoru Kobayashi; Yoshinobu Yamazaki; Nobuo Shibata
Journal:  Yakugaku Zasshi       Date:  2006-03       Impact factor: 0.302

4.  Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study.

Authors:  F Calais Da Silva; P Marquis; P Deschaseaux; J L Gineste; J Cauquil; D L Patrick
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

5.  Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.

Authors:  P Narayan; H Lepor
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

6.  Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.

Authors:  K Höfner; H Claes; T M De Reijke; B Folkestad; M J Speakman
Journal:  Eur Urol       Date:  1999-10       Impact factor: 20.096

7.  Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.

Authors:  B Lukacs; A Leplège; P Thibault; A Jardin
Journal:  Urology       Date:  1996-11       Impact factor: 2.649

Review 8.  Tamsulosin for benign prostatic hyperplasia.

Authors:  T J Wilt; R Mac Donald; I Rutks
Journal:  Cochrane Database Syst Rev       Date:  2003

9.  Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.

Authors:  Leonard S Marks; Marc C Gittelman; Lawrence A Hill; Weining Volinn; Gary Hoel
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450

10.  Alpha1-adrenoceptors and ejaculatory function.

Authors:  M C Michel
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739
View more
  13 in total

1.  Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: profile report.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2011-10-01       Impact factor: 3.923

Review 2.  Silodosin: treatment of the signs and symptoms of benign prostatic hyperplasia.

Authors:  Monique P Curran
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 3.  Adverse effects of common medications on male fertility.

Authors:  Mary K Samplaski; Ajay K Nangia
Journal:  Nat Rev Urol       Date:  2015-06-23       Impact factor: 14.432

Review 4.  Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Authors:  M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou
Journal:  Cell Commun Signal       Date:  2021-07-20       Impact factor: 5.712

5.  Depressive symptoms in patients diagnosed with benign prostatic hyperplasia.

Authors:  Barbara Pietrzyk; Magdalena Olszanecka-Glinianowicz; Aleksander Owczarek; Tomasz Gabryelewicz; Agnieszka Almgren-Rachtan; Andrzej Prajsner; Jerzy Chudek
Journal:  Int Urol Nephrol       Date:  2015-02-12       Impact factor: 2.370

6.  Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations.

Authors:  Lulu K Lee; Amir Goren; Natalie N Boytsov; Craig F Donatucci; Kevin T McVary
Journal:  Patient Prefer Adherence       Date:  2016-07-12       Impact factor: 2.711

7.  Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence.

Authors:  William M Greenberg; Leslie Citrome
Journal:  Neurol Ther       Date:  2015-07-23

8.  Effects of atipamezole and medetomidine administration on seminal variables and functions of erection and ejaculation of the collared peccary (Tayassu tajacu) after electroejaculation.

Authors:  Ariana L C de Paiva; Talyta L Nunes; Maria G C de Oliveira; Alessandro M L de Morais; Erika A A Dos Santos; Alexandre R Silva; Moacir F de Oliveira; Valéria V de Paula
Journal:  BMC Vet Res       Date:  2014-08-08       Impact factor: 2.741

Review 9.  α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?

Authors:  Claus G Roehrborn; Francisco Cruz; Ferdinando Fusco
Journal:  Adv Ther       Date:  2016-10-17       Impact factor: 3.845

10.  A Chinese Medicine Formula "Xian-Jia-Tang" for Treating Bladder Outlet Obstruction by Improving Urodynamics and Inhibiting Oxidative Stress through Potassium Channels.

Authors:  Jie Sun; Wei Shen; Wenjin An; Qiufen Li; Shunan Qiu; Shaobo Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2017-04-19       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.